Buy these 2 ASX health-tech shares that are ready to rocket: Wilson

Consumers still want to stay healthy even through tough economic times.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The health sector is seen by many experts as one that could remain resilient through times of economic distress.

After all, people may cut out dining out or buying a new sofa, but they will still want to remain physically and mentally well.

And with interest rate rises now biting Australian consumers hard, that scenario is well and truly in play.

Here are two ASX shares involved in healthcare that Wilson Asset Management analysts are rating as buys at the moment:

'Momentum is really strong'

The Aroa Biosurgery Ltd (ASX: ARX) has amazingly rocketed almost 46% over the past 12 months, over a time when few non-mining stocks can even claim to be in the black.

Wilson equity dealer William Thompson reckons that trend will continue, calling it a buy.

"It posted a really good sales update in January," Thompson said in a Wilson video.

"They're a New Zealand-based company… They have about seven different products which they're selling in the US."

Aroa Biosurgey is involved in a joint venture with US partner TELA Bio Inc (NASDAQ: TELA), whose reporting next week could prove to be yet another catalyst for the ASX stock.

With a March year end, Aroa's annual result is not far away.

"The momentum is really strong for the company, so it's a buy."

Thompson's peers unanimously agree, with all five analysts surveyed on CMC Markets currently rating Aroa Biosurgery as a buy.

This stock could go anywhere now that supply problems are waning

Resmed CDI (ASX: RMD) has been an old favourite for health investors for decades now, but the share price has struggled in recent times.

Over the past 18 months the stock has lost more than 21% of its value.

According to Wilson equity analyst Anna Milne, the troubles for the business are temporary.

"They've been really struggling to get [computer] chips," she said.

"Now as the broader demand for electronics wanes in this more challenging environment, [Resmed] will find it a lot easier to get these semiconductor chips."

So once that supply problem is fixed, the sky's the limit for the sleep apnoea device market leader.

That's because its nearest rival, Koninklijke Philips NV (AMS: PHIA), was forced out due to a safety recall just under two years ago. 

"With their major competitor Philips still largely out of the market, and will at least be distracted for a few years, we think Resmed is a great company at a fair valuation."

Motley Fool contributor Tony Yoo has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Broker looking at the share price.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Broker Notes

Guess which ASX 200 share offers 12% upside and a 4% dividend yield

Bell Potter just slapped a buy rating on this stock.

Read more »

A man leaps from a stack of gold coins to the next, each one higher than the last.
Broker Notes

Qantas or Telstra share price: Which will climb higher in 2024?

Let's see what top broker Goldman Sachs has to say about these ASX blue-chip stocks.

Read more »

A woman smiles as she sits on the bus using her phone and listening to music through headphones.
Small Cap Shares

3 small-cap ASX shares with 'long runways for growth'

DNR's Sam Twidale reckons investors could do worse than buy these guys for the long run.

Read more »

Woman using laptop for job search
Investing Strategies

2 ASX 200 shares to buy for 'strong growth' at decent prices right now

Searching for a bargain? Here's a pair that Catapult's Dylan Evans has his eyes on at the moment.

Read more »

A Paladin Energy miner wearing a hard hat and protective gear stands in front of a large mining truck and smiles to the camera.
Energy Shares

Uranium is set to boom, and this is the 'premium' ASX stock to buy

Shaw and Partners' Jed Richards reckons these are the shares to buy for the nuclear energy theme.

Read more »

female in hard hat crosses fingers
Investing Strategies

The ASX 200 stock that could get second time lucky

These shares have failed to impress in 2024, but many experts believe it's a bargain buy.

Read more »